LAMA

DRUG7 trials

Sponsors

Queen's University, Novartis Pharmaceuticals, Hoffmann-La Roche, GlaxoSmithKline, Boehringer Ingelheim

Conditions

AsthmaCOPDChronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic Obstructive

Phase 3

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

CompletedNCT01491802

Queen's UniversityCOPD

Start: 2012-01-31End: 2014-09-30Updated: 2017-08-15

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

CompletedNCT05927155

Erasme University HospitalPulmonary Disease, Chronic Obstructive

Start: 2021-06-15End: 2022-03-30Updated: 2023-07-03

Phase 4

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

CompletedNCT01985334

Novartis PharmaceuticalsCOPD

Start: 2014-02-14End: 2016-04-29Updated: 2019-03-19

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

CompletedNCT02537691

Hoffmann-La RocheAsthma

Start: 2015-08-28End: 2017-07-10Updated: 2019-04-09

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

CompletedNCT03467425

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-04-11End: 2019-10-10Updated: 2020-09-07

Unknown Phase

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

CompletedNCT04011475

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2019-12-29End: 2020-10-31Updated: 2022-06-14

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

CompletedNCT05457868

Brigham and Women's HospitalChronic Obstructive Pulmonary Disease

Start: 2021-02-01End: 2023-12-31Updated: 2025-07-28

Related Papers

Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice

BMJ Open Respiratory Research2022-09-013 citations

Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial

2021-09-051 citations

INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata

2020-09-07

Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design

ERJ Open Research2019-10-0115 citations

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

2018-04-1613 citations

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Respiratory Research2017-07-1854 citations

Assessing biomarkers in a real-world severe asthma study (ARIETTA).

2016-04-1415 citations